ORLANDO — In this video from the American Academy of Ophthalmology meeting, Esther M. Bowie, MD, discusses results from the AVONELLE-X trial, the PULSAR trial and the Portal study in wet age-related macular degeneration.
In AVONELLE-X, patients with wet AMD who received Vabysmo (faricimab-svoa, Genentech) were extended from 2 years to 4 years, with approximately 80% of patients extending treatment beyond 12 weeks and about 50% extending beyond 20 weeks. The majority of patients maintained vision and central subfield thickness without any safety issues.
In PULSAR, Bowie, professor in the